|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
oltipraz results in decreased expression of ABCB11 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
oltipraz results in increased expression of ABCB1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC1 protein |
CTD |
PMID:18032408 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression |
ISO EXP |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA oltipraz results in increased expression of ABCC2 mRNA; oltipraz results in increased expression of ABCC2 protein |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:18032408 PMID:25752797 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of ABCC3 mRNA [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA] [oltipraz results in increased expression of ABCC3 protein] which affects the export of Acetaminophen metabolite oltipraz results in increased expression of ABCC3 mRNA; oltipraz results in increased expression of ABCC3 protein |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:22496397 PMID:30114225 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions increases expression |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA] oltipraz results in increased expression of ABCC4 mRNA; oltipraz results in increased expression of ABCC4 protein oltipraz promotes the reaction [ABCC4 protein results in increased transport of Arsenic] |
CTD |
PMID:15833929 PMID:18032408 PMID:20395535 PMID:22496397 PMID:25752797 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions increases expression |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA oltipraz results in increased expression of ABCC5 mRNA |
CTD |
PMID:15833929 PMID:18032408 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA oltipraz results in increased expression of ABCC6 mRNA |
CTD |
PMID:15833929 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases activity increases expression |
ISO |
oltipraz promotes the reaction [ABCG2 protein results in increased transport of Benzo(a)pyrene metabolite] oltipraz results in increased activity of ABCG2 protein oltipraz results in increased expression of ABCG2 mRNA |
CTD |
PMID:15917307 PMID:16837569 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA] oltipraz results in increased activity of AHR protein |
CTD |
PMID:11959854 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases activity |
EXP |
oltipraz results in increased activity of AKR7A3 protein |
CTD |
PMID:9328168 |
|
NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
oltipraz results in decreased expression of ALB mRNA |
CTD |
PMID:9395210 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA] |
CTD |
PMID:17998271 PMID:22496397 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
[Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]; oltipraz results in increased localization of and results in increased activity of CEBPB protein |
CTD |
PMID:12509401 PMID:15319326 PMID:15870285 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES1 mRNA NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA] |
CTD |
PMID:30114225 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES2C mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA] |
CTD |
PMID:22429928 |
|
NCBI chr 1:282,640,752...282,648,319
Ensembl chr 1:282,638,017...282,702,424
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression affects metabolic processing decreases activity affects activity |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]; 2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; oltipraz results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA] CYP1A1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP1A1 mRNA; oltipraz results in increased expression of CYP1A1 protein oltipraz metabolite results in decreased activity of CYP1A1 protein oltipraz affects the activity of CYP1A1 protein |
CTD |
PMID:10775323 PMID:11959854 PMID:15831204 PMID:15890477 PMID:15920769 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression multiple interactions increases activity affects metabolic processing |
ISO EXP |
oltipraz metabolite results in decreased activity of CYP1A2 protein; oltipraz results in decreased activity of CYP1A2 protein oltipraz results in increased expression of CYP1A2 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA] oltipraz results in increased activity of CYP1A2 protein oltipraz inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3,4-dimethylimidazo(4,5-f)quinoline] CYP1A2 protein affects the metabolism of oltipraz |
CTD |
PMID:8625305 PMID:10775323 PMID:15831204 PMID:15920769 PMID:22496397 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity affects activity increases expression |
ISO |
oltipraz metabolite results in decreased activity of CYP1B1 protein oltipraz affects the activity of CYP1B1 protein oltipraz results in increased expression of CYP1B1 mRNA |
CTD |
PMID:10775323 PMID:15890477 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects metabolic processing increases expression |
EXP ISO |
CYP2B1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP2B10 mRNA |
CTD |
PMID:15831204 PMID:15920769 PMID:17627975 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects metabolic processing |
EXP |
CYP2B2 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity increases expression |
ISO |
oltipraz results in decreased activity of CYP2B6 protein oltipraz results in increased expression of CYP2B6 mRNA; oltipraz results in increased expression of CYP2B6 protein |
CTD |
PMID:19833192 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
EXP |
CYP2C11 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2D1 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 7:123,625,641...123,630,045
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects activity |
ISO |
oltipraz affects the activity of CYP2E1 protein |
CTD |
PMID:10775323 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing |
EXP |
CYP3A2 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects metabolic processing |
EXP |
CYP3A23-3A1 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity affects activity |
ISO |
oltipraz metabolite results in decreased activity of CYP3A4 protein; oltipraz results in decreased activity of CYP3A4 protein oltipraz affects the activity of CYP3A4 protein |
CTD |
PMID:10775323 PMID:19833192 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
EXP |
oltipraz results in increased expression of GSTA3 mRNA; oltipraz results in increased expression of GSTA3 protein |
CTD |
PMID:9203627 PMID:9794803 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
EXP ISO |
oltipraz results in increased expression of GSTA2 mRNA; oltipraz results in increased expression of GSTA2 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA] oltipraz results in increased expression of GSTA1 mRNA; oltipraz results in increased expression of GSTA1 protein 2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter] |
CTD |
PMID:9203627 PMID:11309284 PMID:12242683 PMID:12509401 PMID:15155840 PMID:15319326 PMID:15870285 PMID:22496397 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
ISO |
oltipraz results in increased expression of GSTA2 protein |
CTD |
PMID:11309284 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases activity increases expression |
EXP |
oltipraz results in increased activity of GSTA5 protein oltipraz results in increased expression of GSTA5 mRNA; oltipraz results in increased expression of GSTA5 protein |
CTD |
PMID:8051171 PMID:8625305 PMID:9203627 PMID:9328168 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of GSTA1 mRNA; oltipraz results in increased expression of GSTA1 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA] |
CTD |
PMID:11309284 PMID:22496397 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions increases expression |
ISO EXP |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA] |
CTD |
PMID:9203627 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions increases expression |
ISO EXP |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA] oltipraz results in increased expression of GSTM3 protein |
CTD |
PMID:9794803 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of GSTP1 mRNA oltipraz results in increased expression of GSTP1 protein oltipraz results in increased expression of and results in increased activity of GSTP1 protein |
CTD |
PMID:9794803 PMID:15374950 PMID:16950796 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects localization increases expression |
EXP |
oltipraz affects the localization of GSTT1 protein oltipraz results in increased expression of GSTT1 protein |
CTD |
PMID:9794803 PMID:9855024 PMID:10413528 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
oltipraz results in decreased expression of IVL protein |
CTD |
PMID:10769631 |
|
NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of MCL1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of MGMT mRNA oltipraz results in increased expression of and results in increased activity of MGMT protein |
CTD |
PMID:16950796 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA oltipraz results in increased expression of MGST3 mRNA |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr13:85,601,499...85,622,392
Ensembl chr13:85,601,499...85,622,314
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects activity increases activity multiple interactions affects response to substance |
ISO |
oltipraz affects the activity of NFE2L2 protein oltipraz results in increased activity of NFE2L2 protein [oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B35 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES1G mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of SULT3A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT1A6A mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B36 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz binds to and results in increased activity of NFE2L2 protein NFE2L2 protein affects the susceptibility to oltipraz |
CTD |
PMID:11309284 PMID:15833929 PMID:15919853 PMID:19150646 PMID:20086057 PMID:22429928 PMID:22496397 PMID:25752797 PMID:30114225 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity multiple interactions increases expression |
ISO |
oltipraz results in increased activity of NQO1 protein oltipraz promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] oltipraz metabolite results in increased expression of NQO1 protein; oltipraz results in increased expression of NQO1 mRNA; oltipraz results in increased expression of NQO1 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NQO1 mRNA] |
CTD |
PMID:11309284 PMID:12407167 PMID:15919853 PMID:17627975 PMID:18488193 PMID:19144771 PMID:19785463 PMID:22496397 PMID:28959534 PMID:30114225 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein] |
CTD |
PMID:19433268 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
oltipraz results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:15919853 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
oltipraz results in increased expression of SOD2 mRNA |
CTD |
PMID:9395210 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
oltipraz results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16451816 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Doxorubicin results in decreased expression of UCP2 protein] |
CTD |
PMID:29061315 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT1A1 mRNA oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A7 mRNA] |
CTD |
PMID:15374950 PMID:19144771 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases expression |
ISO |
oltipraz results in increased expression of UGT1A5 mRNA |
CTD |
PMID:19144771 |
|
NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions increases expression |
ISO |
oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A6 mRNA] oltipraz results in increased expression of UGT1A6 mRNA |
CTD |
PMID:15374950 PMID:19144771 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2a3 |
UDP glucuronosyltransferase family 2 member A3 |
decreases expression |
ISO |
oltipraz results in decreased expression of UGT2A3 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr14:22,251,507...22,267,899
Ensembl chr14:22,192,970...22,619,968
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
decreases expression multiple interactions |
ISO |
oltipraz results in decreased expression of UGT2B1 mRNA [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:19144771 PMID:22496397 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT2B34 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA] |
CTD |
PMID:22496397 |
|
NCBI chr14:22,597,103...22,619,968
|
|